Table 1.
Demographic and clinical characteristics (N = 3802).
| Characteristic | N (%) | Characteristic | N (%) |
|---|---|---|---|
| Sex | Resistance pattern | ||
| Male | 2461 (64.7) | MDR | 3734 (98.2) |
| Female | 1341 (35.3) | XDR | 68 (1.8) |
| Ethnicity | Resistance type | ||
| Brown-skinned | 1641 (43.2) | Acquired | 3106 (81.7) |
| White | 1403 (36.9) | Primary | 696 (18.3) |
| Black | 644 (16.9) | Disease type | |
| Indigenous | 16 (0.4) | Pulmonary | 3704 (97.4) |
| Yellow | 6 (0.2) | Both | 69 (1.8) |
| Ignored | 92 (2.4) | Extrapulmonary | 29 (0.8) |
| Age group | Pulmonary disease | ||
| <60 years | 3530 (92.8) | Bilateral | 2673 (70.3) |
| 60 and more | 272 (7.2) | Unilateral | 1099 (28.9) |
| Schooling (years) | Normal | 30 (0.8) | |
| None | 266 (7.0) | Pulmonary cavity | |
| 1–3 | 718 (18.9) | Yes | 3087 (81.2) |
| 4–7 | 1377 (36.2) | No | 685 (18.8) |
| 8–11 | 854 (22.5) | Regimen | |
| ≥12 | 235 (6.2) | Individualized | 464 (12.2) |
| Ignored | 352 (9.3) | Standardized | 3338 (87.8) |
| MDRTB treatment | DOT | ||
| New case | 3106 (81.7) | Yes | 2761 (72.6) |
| After default | 295 (7.8) | No | 1041 (27.4) |
| After failure | 265 (7.0) | ||
| Relapse | 106(2.8) | ||
| Other | 30 (0.7) | ||
MDR, multidrug-resistance; XDR, extensively drug-resistant; DOT, Directly Observed Treatment.